发明名称 Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2
摘要 The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Nuclear factor (erythroid-derived 2)-like 2 (NRF2), in particular, by targeting natural antisense polynucleotides of Nuclear factor (erythroid-derived 2)-like 2 (NRF2). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of NRF2.
申请公布号 US9464287(B2) 申请公布日期 2016.10.11
申请号 US201013256720 申请日期 2010.03.16
申请人 CuRNA, Inc. 发明人 Collard Joseph;Khorkova Sherman Olga;Coito Carlos
分类号 C12N15/113;C07H21/04;A61K48/00;A61K31/7088;A61K31/713 主分类号 C12N15/113
代理机构 CuRNA, Inc. 代理人 CuRNA, Inc. ;Browder Monte R.
主权项 1. A method of upregulating a function of and/or the expression of a Nuclear factor (erythroid-derived 2)-like 2 (NRF2) polynucleotide having SEQ ID NO: 1 in patient cells or tissues in vivo or in vitro comprising: contacting said cells or tissues with at least one single stranded antisense oligonucleotide of about 16 to 34 nucleotides in length that targets and specifically hybridizes to a region of a natural antisense polynucleotide of the Nuclear factor (erythroid-derived 2)-like 2 (NRF2) polynucleotide, said natural antisense polynucleotide consisting essentially of SEQ ID NO: 9 thereby upregulating a function of and/or the expression of the Nuclear factor (erythroid-derived 2)-like 2 (NRF2) polynucleotide in patient cells or tissues in vivo or in vitro.
地址 Miami FL US